Clinical Trials · NCT00598871
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- ReGenTree, LLC
- Enrollment
- 12
- Start date
- Dec 2007
- Locations
- 5 sites, United States
- Primary endpoint
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) After Treatment With Thymosin Beta 4 in the Target Eye of Diabetic Patients During Vitrectomy